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The nuclear orphan receptor CAR is active in the
absence of ligand with the unique capability to be
further regulated by activators. A number of these
activators, including phenobarbital, do not directly
bind to the receptor. Considered a xenobiotic
sensing receptor, CAR transcriptionally modifies
the expression of genes involved in the metabolism
and elimination of xenobiotics and steroids in re-
sponse to these compounds and other cellular me-
tabolites. Its hepatic expression pattern endows
the liver with the ability to protect against not only
exogenous but also endogenous insults. The
mechanism of CAR activation is complex, involving
translocation from the cytoplasm to the nucleus in
the presence of activators, followed by further ac-
tivation steps in the nucleus. Although this mech-
anism remains under investigation, we have sum-
marized here the cellular signaling pathways
elucidated so far and speculate on the mechanism
by which CAR activators regulate gene expression
through this network. (Molecular Endocrinology 18:
1589–1598, 2004)
WHEN A NOVEL HUMAN orphan nuclear receptorwas cloned and named MB67 in 1994 (1), no
one realized the impact it would have on the field of
xenobiotic and steroid metabolism. This receptor,
highly expressed in the liver, was capable of het-
erodimerizing with the 9-cis-retinoic acid receptor
(RXR) and transactivating an empirical set of retinoic
acid response elements in the absence of ligand (1). In
1997 a closely related mouse receptor with the same
constitutive retinoic acid response element transacti-
vation ability was identified, leading to the term con-
stitutive activator of retinoid response (CAR) being
coined (2), later shortened to constitutive active
receptor for both mouse and human receptors. Sub-
sequently, CAR has become best known for its
ability to regulate induction of the CYP2B gene
family by phenobarbital (PB) and PB-like inducers
[e.g. chlorpromazine, phenytoin, dichlorodiphenyltri-
chloroethane, 1,4-bis[2-(3,5-dichloropyridyloxy)]ben-
zene (TCPOBOP) and polychlorinated biphenyls],
thereby revealing its function as a xenobiotic-sensing
nuclear receptor (3–5). The generation of CAR-null
mice confirmed that CAR is essential for Cyp2b10
responses to PB-like inducers (6, 7) and expanded the
role of CAR in gene regulation by promoting the iden-
tification of numerous genes that are regulated by this
receptor (7–11).
CAR generally binds to and activates transcription
via DR4 motifs, such as the two nuclear receptor ele-
ments that flank the nuclear factor 1 site within the
51-bp PB-responsive enhancer module (PBREM) of
Cyp2b10 (4, 12, 13). The orphan nature of CAR gen-
erated a search for an endogenous ligand, especially
in light of the receptor’s apparent constitutive activity.
Two androstane metabolites, 5-androst-16-en-3-ol
(androstenol) and 5-androstan-3-ol (androstanol)
were identified as CAR ligands but repressed the con-
stitutive activity (14). Foresight was shown with the
acronym CAR, which was then also applied to consti-
tutive androstane receptor. In many ways CAR resem-
bles a classic steroid hormone nuclear receptor such
as the glucocorticoid receptor (GR), being retained in
the cytoplasm until exposed to activators. However,
the constitutively active nature of CAR and the fact
that many of its activators including PB do not bind
directly to the receptor1 reflects a novel mechanism,
Abbreviations: AF2, Activation function 2; AhR, aryl hydro-
carbon receptor; CAR, constitutive active/androstane recep-
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receptor; GRE, glucocorticoid response element; GST, glu-
tathione-S-transferase; Hsp, heat shock protein; LB, ligand
binding; MRP, multidrug resistance-associated protein; NLS,
nuclear localization sequence; NO, nitric oxide; PB, pheno-
barbital; PBREM, PB-responsive enhancer module; PP2A,
protein phosphatase 2A; PXR, pregnane X receptor; SRC,
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ropyridyloxy)]benzene; UGT, uridine diphosphate-glucuronyl
transferase.
Molecular Endocrinology is published monthly by The
Endocrine Society (http://www.endo-society.org), the
foremost professional society serving the endocrine
community.
1 Due to the complex nature of CAR regulation, in this
review a ligand is defined only by its ability to bind directly to
the receptor, whereas an activator or repressor is defined by
its ability to modulate receptor activity without direct binding
to the receptor. For example, TCPOBOP is considered both
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advances in the understanding of which will be exam-
ined herein.
Considering many CAR activators are xenobiotics,
CAR (NR1I3) (15) joined its closest mammalian rela-
tive, the pregnane X receptor (PXR, NR1I2) (16, 17), as
a xenosensor (18). Since then, receptors related to the
NR1I family have been identified in nonmammalian
species: the chicken xenobiotic receptor and nhR8 in
Caenorhabditis elegans (19, 20). This indicates that
xenosensing activity is an ancient conserved function
for this family, as the ability of nhR8 to contribute
resistance to the toxins colchicine and chloroquine
has been shown (20). In addition, the Xenopus benzo-
ate X receptors  and  (21), the teleost fish Fugu
rubripes fr078207 (22), and the Drosophila HR98 (23)
are closely related to the NR1I family. However, their
role in xenosensing activity has hitherto been contro-
versial or unconfirmed. The majority of these nonmam-
malian receptors resemble PXR more closely than
CAR (22), suggesting that CAR may be a mammalian
receptor that diverged from PXR at a later point in
evolution. Although CAR is most frequently identified
as a xenobiotic-sensing receptor, it may also have a
role in endocrine homeostasis, because it regulates
enzymes that metabolize xenobiotics, which are also
involved in the metabolism of endogenous signaling
compounds such as steroid hormones. Given the ca-
veat that CAR exhibits species differences, this review
focuses primarily on the role, function, and activation
mechanism of mouse CAR.
THE HEPATOTOXIC ROLE OF CAR
CAR coordinates the regulation of multiple genes re-
sulting, in most cases, in the net clearance of com-
pounds from the blood by transporters such as or-
ganic anion transporter protein 2 and their metabolic
detoxification within the hepatocyte by cytochrome
P450s (CYPs), NADPH-cytochrome P450 reductase,
and transferases. For example, sleep induced by PB
was prolonged in CAR null mice (Fig. 1). Similarly, the
muscle relaxant zoxazolamine resulted in paralysis in
wild-type mice that was avoided by pretreatment with
CAR activators but was prolonged in CAR knockout
mice (6). Thus, CAR-coordinated induction of meta-
bolic activity increases elimination of these drugs in a
protective manner. The induction of 5-aminolevulinic
acid synthase 1 by PB suggested that CAR also co-
ordinates the induction of heme biosynthesis to ac-
commodate increased CYP levels; however, induction
studies with PB and TCPOBOP in CAR null mice indi-
cate that 5-aminolevulinic acid synthase 1 regulation is
independent of CAR (7, 8). CAR can repress the genes
that encode enzymes involved in signal transduction,
fatty acid oxidation, and/or energy metabolism, e.g.
phosphoenolpyruvate carboxykinase 1, enoyl coen-
zyme A isomerase, and carnitine palmitoyl transferase
1 (7). Repressing such physiological processes may
provide a further mechanism for cells to cope with
toxicity. CAR hepatoprotective action includes block-
age of the induction by PB of certain genes, which
were identified by their induction in only CAR null mice.
For example CAR prevents the induction of CYP4A,
the major microsomal lipid peroxidase, by PB and
coordinately mediates the induction of superoxide dis-
mutase 3, which together may suppress oxidative
stress (7). This CAR-mediated defense system against
chemical toxicity is as applicable to endogenous as to
xenobiotic compounds and may have evolved to deal
with both.
CAR as a Protective Factor
Bilirubin, an oxidative end product of heme catabo-
lism, is one of the most toxic natural breakdown prod-
ucts in the body. Accumulation is associated with
jaundice that can chronically lead to neurotoxicity and
eventually fatal encephalopathy (24, 25). Glucuronida-
tion by uridine diphosphate-glucuronyl transferase
UGT1A1 is the major detoxification pathway of biliru-
bin, and the conjugate is secreted across the bile-
canicular membrane of hepatocytes into the bile by an
active transporter multidrug resistance-associated
protein (MRP) 2. For a long time it has been known that
PB can decrease elevated bilirubin levels. This is now
revealed to be due to the ability of CAR to activate the
expression of known components of the bilirubin path-
way including UGT1A1, organic anion transporter pro-
tein 2, MRP2, and glutathione-S-transferase (GST)A1
(25). CAR can activate the 290-bp gtPBREM (3483/
a ligand and an activator, whereas PB is only an activator due
to its indirect activation mechanism.
Fig. 1. PB-Prolonged Sleep in CAR-Null Mice
Male C3H (open bars) and CAR-null (shaded bars) mice
(n  10 in each group; mean weight, 26  5 g) were ip
injected with 100 mg PB per kg body weight at 0 and 24 h to
examine the effect of PB on its own metabolism. From the
time of the second injection, sleep duration was recorded as
the time when the mice were able to right themselves.
1590 Mol Endocrinol, July 2004, 18(7):1589–1598 Swales and Negishi • Minireview
3194) in the UGT1A1 gene (24). Originally, two DR4
and one DR3 elements (named NR4, gtNR1, and NR3,
respectively) were localized in the gtPBREM, of which
gtNR1 provided the major CAR binding and activation
site, although the other two sites were also required for
optimal gtPBREM activity. Later, an additional DR3
element was found immediately downstream of NR4
within the gtPBREM to which both CAR and PXR
could bind (26). Although this DR3 was implicated in
PXR activation by rifampicin, it remains to be deter-
mined whether this is the primary site conferring rif-
ampicin responsiveness to the UGT1A1 gene. The
gtPBREM may be a general DNA sequence regulating
the response to various xenobiotics as well as endog-
enous compounds, because it also contains an active
aryl hydrocarbon receptor (AhR) binding site (27). It
has been claimed that CAR further promotes bilirubin
excretion by inducing the biliary transporter MRP2 in
rodent hepatocytes (25, 28). Yet lack of significant
MRP2 induction by CAR activators infers that the role
of CAR is unclear (29, 30). An additional biliary trans-
porter MRP3, with overlapping substrate specificity to
MRP2, is also PB inducible, but PB induction of MRP3
appears to be CAR independent (31). Thus the role of
CAR in regulating these MRPs is not clear. The defen-
sive role of CAR includes protection against bile acid
toxicity in the absence of key bile acid sensors farne-
soid X receptor (FXR) and PXR as shown in FXR PXR
double knock out mice in which cholic acid elevated
the levels of CAR and CYP2B mRNA, and pretreat-
ment with PB or TCPOBOP induced a collection of
target genes, incorporating those involved in protec-
tion against bilirubin toxicity, which reduced serum
bile acid and bilirubin concentration (32). Thus CAR
acts to complement FXR and PXR to coordinate pro-
tection against hepatic bilirubin acid toxicities.
CAR as a Risk Factor
This defense against toxicity, by increasing metabo-
lism, may often promote the toxicity it purports to
prevent. CAR was identified recently as a key regulator
of acetaminophen metabolism and hepatotoxicity (33).
In addition to the well-known GSTs that are induced by
PB, CAR also regulates GSTPi, the enzyme that en-
hances glutathione depletion and so promotes acet-
aminophen toxicity (33–36). High-dose acetamino-
phen-induced toxicity occurred in wild-type but not
CAR null mice (33), consistent with the resistance to
this toxicity in GSTPi null mice (36). Similarly, CAR
activators PB and TCPOBOP sensitize mice to co-
caine hepatotoxicity, which is absent in CAR null mice
(6). Nitric oxide (NO) may protect cells from such
xenobiotic-induced toxicity by its antioxidant proper-
ties, which are able to terminate lipid peroxidation and
oxidative stress. CAR regulates the human-inducible
NO synthase gene via a DR4 element (37). However,
prolonged exposure to NO will shift the cellular redox
state to one more oxidized, via oxidation of thiols such
as glutathione. Thus, chronic CAR activation may pro-
mote hepatotoxic effects.
THE EXTRAHEPATIC ROLE OF CAR
In addition to liver, CAR is also highly expressed in the
epithelial cells of small intestine villi, where it was
essential for the modest induction of Cyp2b10 by
TCPOBOP and PB observed by Wei et al. (6, 9). How-
ever, a previous study showed lack of CYP2B10 in-
duction in the intestine by PB (38). As CAR acts as a
xenosensor to protect from exogenous insults, its ex-
pression at a point of entry into the body is reasonable.
Clinical studies of orally administered drugs demon-
strate that intestinal drug metabolism can significantly
reduce oral bioavailability (39). Thus, CAR-mediated
induction of Cyp2b10, phase II GSTs 1 and 1, and
the broad specificity efflux pump Mdr1a in the intes-
tine may enhance first-pass metabolism of xenobiot-
ics. CAR is also expressed at low levels in both mouse
and human heart, skeletal muscle, brain, kidney, and
human lung (1, 2), but the physiological role of the
receptor in these tissues has not been investigated
thoroughly, especially in kidney where the CAR target
gene Cyp2b10 is not expressed (38).
CAR IN ENDOCRINE HOMEOSTASIS AND
DISRUPTION
CAR and other xenosensors, such as PXR, may form
a regulatory network that governs endocrine ho-
meostasis by altering hormone metabolism. The first
endogenous modifiers of CAR activity identified were
the steroids androstanol and androstenol, which in-
hibit the constitutive activity of the receptor by directly
dissociating the interaction between CAR and the ste-
roid receptor coactivator SRC-1 (14). Similarly, pro-
gesterone and testosterone repress constitutive CAR
activity (40), but at greater concentrations than the
circulating adult levels (41, 42). In contrast, pharma-
cological levels of active estrogens estradiol (E2) and
estrone and the progesterone metabolite pregnane
3,20-dione can activate rodent and human CAR, re-
spectively, above their constitutive levels (40, 43).
Whereas in male mice experiments indicate that en-
dogenous androgen may repress CAR transcriptional
activity (40, 44), the physiological relevance of steroid
hormone regulation of CAR activity, especially in hu-
mans, remains to be resolved.
As CYP2B, a major target for CAR activation, me-
tabolizes both estrogen and androgen and CAR-
regulated UGT1A1 glucuronidates estrogens, induc-
tion of these enzymes due to CAR activation by xeno-
and endobiotics could increase steroid hormone ca-
tabolism (24, 40, 45, 46). Sulfation is catalyzed by
sulfotransferases (47) that are generally reported as
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noninducible by PB in humans and mice, although
Maglich et al. (48) observed that newly identified hu-
man CAR activator 6-(4-chlorophenylimidazo[1,1-b]
(1, 3)thiazole-5-carbaldehyde O-3,4-dichlorobenzyl)oxime
(CITCO) induced human sulfotransferase 1A1 mRNA in
one of three samples examined. However, CAR may
augment steroid sulfation in the presence of PB by
transactivating the 3-phosphoadenosine 5-phos-
phosulfate synthase 2 gene (7), which is responsible
for synthesis of the biological sulfate donor 3-phos-
phoadenosine 5-phosphosulfate (49). Thus, xenobi-
otics, through CAR, may influence the different stages
of steroid hormone homeostasis by inducing the CYPs
and transferases involved in the metabolism of estro-
gens and their precursor steroids.
Further evidence that CAR may be involved in ste-
roid hormone metabolism came when a distal glu-
cocorticoid response element (GRE) was identified in
the human CAR gene, 4.4 kb upstream of the tran-
scription start site, which was conserved in the murine
CAR gene (50). The GRE consists of two imperfect
GRE half-sites separated by three nucleotides (GGAA-
CAacaAGGGCA) to which GR homodimers can bind
(50). This provides a mechanism for the CAR induction
previously observed by submicromolar concentrations
of dexamethasone in primary human hepatocytes (51,
52), the potentiation of CYP2B2 and CYP2B10 induc-
tion by PB in the presence of dexamethasone in rats
and mice, respectively (53, 54), and the fact that GR
was found to be essential for dexamethasone-induced
CYP2B expression (55). CAR, being a primary glu-
cocorticoid receptor-response gene, adds a further
level of complexity to endocrine homeostasis.
REGULATORY MECHANISMS OF CAR
ACTIVATION
The mechanism of CAR activation is novel. In contrast
to most orphan nuclear receptors that reside in the
nucleus, CAR is compartmentalized in the cytoplasm
in a manner similar to classic steroid hormone nuclear
receptors such as GR (12). Retention in the cytoplasm
prevents chronic activation of CAR target genes and
allows tight regulation of the receptor’s activity. Acti-
vators either bind directly to CAR, consistent with
other family members, or act indirectly, such as PB
and bilirubin, which do not bind to the receptor but
translocate CAR to the nucleus, making translocation
an initial step in the CAR activation process (12, 25,
56). A phosphorylation cascade is involved in regulat-
ing CAR translocation, yet elucidation of the CAR ac-
tivation mechanism has proved difficult due to the fact
that CAR accumulates spontaneously in the nucleus of
transformed cell lines regardless of activation state
(12). A protein capable of retaining CAR in the cyto-
plasm of transformed cell lines has now been identi-
fied (57), expanding the possibilities for future re-
search. Moreover, it has become apparent that
translocation alone does not determine CAR activa-
tion, but that additional regulation is required in the
nucleus. Investigations from our laboratory and those
of others lead us to propose the following mechanisms
for CAR activation (Fig. 2).
Structural Aspect of CAR
CAR is characterized by high constitutive activity in
cell-based transfection assays. In computer-gener-
ated models CAR contains the conserved activation
function 2 (AF2) domain and a standard ligand binding
(LB) cavity lined with hydrophobic residues, support-
ing the ability of this receptor to bind specific ligands
such as androstanol, TCPOBOP, and CITCO (48, 58–
61). The ability of CAR to respond to activators that do
not directly bind to the receptor infers regulation by
other means such as phosphorylation, yet the N-
terminal ligand-independent function 1 (AF1) domain
that is associated with such regulation in other recep-
tors is shortened in CAR to only 10 and 20 amino acid
residues in the mouse and human receptors, respec-
tively. Choi et al. (2) showed that mouse CAR lost
constitutive activity after AF2 deletion or mutations
(Leu352Ala or Glu355Ala). Thus, CAR appears to
maintain its AF2 domain in an active conformation that
facilitates interactions with coactivators in the ab-
sence of ligand, whereas LB binding optimizes the
position of the AF2 domain for further coactivator re-
cruitment (14, 43, 58, 62). Yet the question remains:
how does CAR maintain the AF2 domain in an active
conformation in the absence of ligand? Recent x-ray
crystal structures of five different CARs in which the
AF2 domains are in the active conformation provided
structural interpretations of their activities (63–68).
Moreover, the LB cavity is filled by an unexchangeable
fatty acid in the hepatocyte nuclear factor 4 (63, 65) or
is tightly packed with bulky residue side chains in the
estrogen-related receptor ERR (64) and nuclear-re-
lated receptor Nurr1 (68) structures, respectively. On
the other hand, a rigid extended helix 2 appears to
constrain the AF2 domain into the active conformation
in liver receptor homolog-1, whereas the receptor’s
large LB cavity remains empty (67). Activation of the
Drosophila Nurr1 homolog DHR38 is dependent on a
preactivated heterodimerization partner and on ecdys-
teroids, which are too large to fit into the LB cavity (66).
This activation mechanism remains to be clarified but
may aid explanation of the LB-independent activation
of CAR, although CAR forms a nonpermissive het-
erodimer with RXR. Accordingly, none of the current
x-ray crystal structures, when compared with comput-
er-generated models of CAR, are easily adopted to
explain the constitutive activity of the receptor.
Uniquely, despite its constitutively active nature, CAR
is tightly regulated in vivo in liver, thus conferring re-
sponsiveness to activators.
Although a broad range of structurally dissimilar
xenobiotics and endogenous compounds can modu-
late CAR constitutive activity, it is known that mutation
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of a single amino acid residue in CAR is able to alter
a given specificity. Mutation of Thr350 in hormone-
responsive mouse CAR to methionine, as in nonre-
sponsive human CAR, could abolish the repression by
testosterone and progesterone and reactivation by es-
trogen (69). However, mutation of this residue did not
change the repression of CAR activity by Ca2/cal-
modulin kinase inhibitor KN62, suggesting that the
structural basis for hormone repression differs from
that for repression by xenochemicals (69). In support
of this hypothesis, only mutation of Leu352, a pre-
dicted key residue for AF2 interaction with coactiva-
tors, could abolish responsiveness to TCPOBOP and
mutation of either residue Cys357 or Tyr336, which are
proposed to interact with and stabilize helix 12, abol-
ished the repressive effect of androstanol on transcrip-
tional activity (70). Thus it appears that diverse CAR
ligands interact with different residues to exert their
effects, corresponding to the receptor’s large LB cav-
ity and predictions of alternate LB orientations (48, 60,
61). Four naturally occurring in-frame splice variants of
the human CAR gene compromise DNA binding, co-
activator recruitment, and transcriptional activation,
providing an additional source for functional variability
and possible alternate interaction sites for those acti-
vators unable to bind directly to wild-type CAR (71).
This promiscuous nature is reminiscent of CYP en-
zymes that exhibit broad substrate specificity yet de-
termine a given activity by a single amino acid residue
(72, 73). However, CAR is unique in the sense that
activators do not necessarily directly bind to regulate
CAR.
NUCLEAR TRANSLOCATION MECHANISM
Ligand-Independent Translocation
CAR is retained in the cytoplasm of untreated cells and
translocates into the nuclei of liver cells after treatment
Fig. 2. Mechanism of CAR Activation
CAR translocation can be triggered by either direct ligand binding to the receptor, or indirectly, via a partially elucidated signal
transduction pathway. CAR exists in a complex with Hsp90, retained in the cytoplasm by the cochaperone CCRP. Indirect
activators or the direct binding of ligands to CAR subsequently recruits PP2A to the complex. Once in the nucleus, further
activation steps involving calmodulin-dependent kinase and recruitment of coactivators occur before DNA binding and tran-
scriptional activation of target genes.
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with PB or PB-like inducers to activate PB-responsive
genes (12) (Fig. 2). In contrast to steroid hormone
receptors and AhR, which are triggered by direct LB,
nuclear translocation of CAR does not require the
direct binding of activators. Although PB does not bind
directly to either mouse or human CAR, it translocates
the receptors into the nucleus in mouse liver (12, 56).
The potent PB-type activator TCPOBOP binds directly
to mouse CAR (43) and translocates the receptor into
the nucleus (12). On the other hand, human CAR does
not bind TCPOBOP (43), yet is translocated after ex-
posure to TCPOBOP when the receptor is expressed
in the livers of wild-type mice (56). Therefore, activa-
tors can promote the nuclear translocation of CAR by
a ligand-independent process, regardless of their re-
ceptor binding ability. Nuclear translocation of PXR
appears to be regulated by a bipartite nuclear trans-
location signal (NLS) located in the DNA binding do-
main (74). In CAR, the nuclear import activity of the
corresponding NLS seems to be weakened by muta-
tions and thus does not regulate translocation (74).
CAR lacking its AF2 domain translocated normally into
the nucleus in mouse liver (56), whereas the translo-
cation of the vitamin D receptor and GR is dictated by
the presence of their AF2 domains (Ref. 75 and Zelko,
I., unpublished observations). In fact, deletion of the
DNA binding domain or everything except the C-
terminal half of the LB domain (residues 181–348) did
not affect CAR nuclear translocation in mouse liver
(56, 76). Thus, neither the AF2 domain nor a general
NLS appeared to be involved in regulating CAR nu-
clear translocation. Instead, xenobiotic-responsive
nuclear translocation activity was delineated to a
leucine-rich peptide (L/MXXLXXL) distinct from the
AF2 domain, named the xenobiotic response signal,
within the 30 C-terminal residues of human and mouse
CAR (56). Therefore, the regulatory mechanism under-
lying CAR nuclear translocation may be chemical-de-
pendent activation of the xenobiotic response signal.
Heat Shock Protein (Hsp)90 Complex and Protein
Phosphatase 2A (PP2A)
The CAR translocation process is sensitive to the pro-
tein phosphatase inhibitor okadaic acid, suggesting
that it is regulated by a phosphorylation-dependent
pathway (12). This signal transduction pathway has
been confirmed by recent work demonstrating that a
CAR-Hsp90 complex recruits PP2A upon treatment
with PB (77). Before PB treatment, CAR exists as a
complex with Hsp90 in the cytoplasm of noninduced
mouse liver cells colocalized with microtubules (57,
77). As low concentrations of okadaic acid preferen-
tially inhibit PP2A, it appears likely that PP2A recruit-
ment leads CAR to translocate to the nucleus.
Geldanamycin also inhibited the nuclear translocation
of CAR by interrupting the chaperoning function of
Hsp90, suggesting that it is also required for nuclear
translocation (77).
Cochaperone
Whereas nuclear translocation occurs in the liver and
in primary hepatocyte cultures via this signal transduc-
tion cascade, in transformed cell lines CAR accumu-
lates spontaneously in the nucleus (12). This contrasts
sharply with GR and AhR that are retained in the
cytoplasm of hepatoma cells and translocate into the
nucleus in response to agonists (56, 78). The cytoplas-
mic retention of GR and AhR relies on their formation
of complexes with Hsp90 and cochaperones (79–81).
We have now identified such a cochaperone for CAR,
cytoplasmic CAR retention protein (CCRP), which re-
tains the receptor in the cytoplasm when expressed in
HepG2 cells (57). CCRP directly binds to CAR through
the LB domain in a 1:1 molecular ratio and then me-
diates the binding of CAR to Hsp90 and the cytoplas-
mic accumulation of the complex in HepG2 cells (57).
Tetratricopeptide repeat motifs, as found in CCRP,
have been reported to recruit PP2A (82); therefore
CCRP may be involved in the CAR-Hsp90-PP2A com-
plex described by Yoshinari et al. (77).
ACTIVATION PROCESS IN THE NUCLEUS
Due to the correlation of nuclear translocation with
target gene induction and the constitutive activity of
CAR, it was believed initially that nuclear translocation
led to the activation of CAR. However, our group has
recently provided evidence to the contrary. The Ca2/
calmodulin-dependent kinase inhibitor KN-62 re-
pressed induction of CYP2B10 mRNA as well as the
activation of an NR1-reporter gene by both PB and
TCPOBOP in mouse primary hepatocytes, but it did
not prevent PB-induced accumulation of CAR in the
nuclei, suggesting that CAR may undergo a distinct
activation process in the nucleus (83, 84). Retinoid-
related orphan receptor-, another constitutively acti-
vated nuclear orphan receptor, can be further acti-
vated by calmodulin-dependent kinase IV, although
the receptor itself is not phosphorylated, and this ac-
tivation is mediated by a small protein yet to be char-
acterized (85). Because the versatile CAR regulates
specific, yet diverse, functions, the activation mecha-
nism remains enigmatic, although it may resemble, in
part, the regulatory mechanism of retinoid-related or-
phan receptor-.
COACTIVATORS
An expanding number of coactivators and corepres-
sors that interact with CAR have been identified, such
as SRC-1 (14, 43, 62), GR-interacting protein 1 (86),
Xenopus SRC-3 (87), and peroxisomal proliferator-
activated receptor- coactivator 1 (88), which may
simultaneously regulate CAR via different regions of
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the receptor. However, how they activate CAR in liver
where the receptors’ activity is tightly controlled has
not been addressed directly. Whether peroxisomal
proliferator-activated receptor- coactivator 1, a so-
called inducible coactivator, can also be a xenobiotic-
responsive coactivator and/or whether a yet unidenti-
fied coactivator may regulate CAR in response to
xenobiotics is an urgent question for investigation.
Although there are no reports on the role of coactiva-
tors on chromatin structure in CAR-mediated PB in-
duction, evidence was provided recently, which sug-
gests that the coactivators cAMP response element
binding protein and cAMP response element binding
protein-associated factor are recruited to a 556-bp
enhancer region, similar to the PBREM, in the chicken
CYP2H1 gene by chicken xenobiotic receptor after PB
exposure. These coactivators acetylate the chromatin,
allowing activation of the CYP2H1 promoter (89). As
PB substantially alters chromatin structure in the PB-
responsive unit and proximal promoter of CYP2B1/2
(90), it is likely that CAR also recruits coactivators with
histone acetylase activity in mammals.
CONCLUSION
CAR has the potential to impact numerous signaling
pathways via the genes it modulates directly and by its
interference with other nuclear receptor signaling
pathways. This creates a unique integrative mecha-
nism to modulate the metabolism of not only xenobi-
otic substances but also endogenously produced ste-
roids and dietary factors. Unlike its closest relative
PXR, the function of which relies solely on ligand bind-
ing, CAR functions ligand independently and can be
regulated by both direct ligand binding and indirect
activation processes. In light of this, the elucidation of
the mechanistic aspects of CAR regulation is ex-
tremely important to divulge the pathways involved
and the evolutionary drive that separated CAR from
PXR. Whereas much of the research into CAR regula-
tion focuses on the effects of xenobiotics and in par-
ticular the unusual PB, which does not bind directly to
CAR, we hope that this review has illustrated that the
insights provided are equally applicable to the recep-
tor’s role in the metabolism of endogenous com-
pounds. It now appears that the mechanism of CAR
nuclear translocation and activation is much more
complex and tightly regulated than initially believed
and that exciting research in this area remains for the
future.
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